Protocol No.: HQP1351AG301

Title
A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Olverembatinib Combined with Chemotherapy Versus Investigator s Choice of TKI Combined with Chemotherapy in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) (POLARIS-1)
Principal Investigator
Emadi, Ashkan
Phase
III (Cancer Control)
Age Group
Adult
Applicable Disease Site
Leukemia
Participating Institution
Mary Babb Randolph Cancer Center
Contact
Caitlin Slack, BS
Clinical Research Coordinator

View on ClinicalTrials.gov